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Abstract 
The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated 
in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period 2007–2015). 
The 43.2% had a CD4 nadir ≤100 cells/mm3, 64.1% were treatment-experienced, and 36.5% had failed to >3 
lines of antiretroviral therapy. Nonetheless, the rate of virological suppression (HIV-RNA <50 copies/ml) in 
naïve patients was 63%, 66.7%, and 63.6% at 48, 96, and 144 weeks, respectively. The rate of virological 
suppression in treatment-experienced patients was 62.7%, 78.7%, and 79.1% at 48, 96, and 144 weeks, 
respectively. No differences were observed according to the immunovirological status neither dosage of 
DRV/r. Most of them (82.6%) maintained DRV/r treatment. Causes for DRV/r discontinuation were mainly 
gastrointestinal and cutaneous adverse events (10.5%), switch to simplification treatment strategies (3.5%) 
and virological failure (1.7%). These findings demonstrate the prolonged efficacy and tolerability of DRV/r 
even in multi-treated HIV+ patients with an unfavorable immunovirological status. 
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INTRODUCTION 
The goal of antiretroviral treatment (ART) is to achieve and maintain virological suppression 
in HIV+ patients. The ART options have been significantly improved in the last years with a 
progressive introduction of novel highly efficacy antiretroviral drugs with a better safety and 
tolerability profiles than the previous ones. Now therefore, the selection of an antiretroviral 
regimen to treat HIV infection can and should be individualized, considering several factors 
including patient's co-morbidities, adherence, adverse events or baseline drug resistance mutations 
[DHHS, 2015; EACS, 2015]. 
 
Darunavir boosted with ritonavir (DRV/r) has been approved for the treatment of HIV 
infection by the Food and Drug Administration in 2006 and by the European Medicines Agency in 
2007. DRV/r represents a second-generation of protease inhibitors (PIs) with a higher genetic 
barrier for resistance than the first-generation [Poveda et al., 2006, 2007]. Indeed, due to its proven 
efficacy in the presence of PIs resistance mutations, the initial target population for DRV/r was 
treatment-experienced HIV-infected patients with limited therapeutic options [Clotet et al., 2007]. 
Later, several clinical trials demonstrated its efficacy in both naïve and treatment-experienced 
HIV+ patients [Madruga et al., 2007; Ortiz et al., 2008]. Indeed, in the last HIV treatment 
guidelines, a DRV/r-based regimen is a recommended treatment strategy for initial therapy, 
especially for patients with poor adherence due to its high genetic barrier to resistance [DHHS, 
2015; EACS, 2015]. 
 
The use of DRV/r as monotherapy was also evaluated as simplification treatment strategy to 
reduce nucleoside reverse transcriptase inhibitors (NRTIs) toxicity, to prevent the selection of 
resistance mutations to other drug families and to reduce costs. This strategy is able to maintain 
HIV-RNA suppression in the long-term in a group of selected HIV+ patients with a stable control 
of plasma viremia [Katlama et al., 2010; Gazzard et al., 2011; Arribas et al., 2016]. More recently, 
dual therapy (i.e., DRV/r with raltegravir, lamivudine or etravirine) has shown a good profile of 
efficacy and safety. Therefore, it could be considered a feasible option for the optimization of ART 
[Borghetti et al., 2014; Raffi et al., 2014; Vingerhoets et al., 2015]. 
 
However, few studies have evaluated the long-term efficacy and safety of regimens including 
DRV/r in the real life and outside clinical trials [Young et al., ; Benea et al., 2014; Biscione et al., 
2014; Ribeiro et al., 2014]. Herein, we assessed the clinical experienced with DRV/r based on 
efficacy, safety and tolerability parameters in a large cohort of HIV+ patients in Northwest Spain 
since its approval since 2007 until nowadays. 
METHODS 
This is a retrospective observational study, which included HIV+ patients over 18 years old in 
clinical follow-up at the University Hospital of A Coruña (Spain) who have received ART 
including DRV/r between 2007 and September 2015. The research protocol has been approved by 
the regional ethic committee (“Comité Ético de Investigación Clínica de Galicia”, register code 
2014/500) and only patients who have signed the informed consent were included. This hospital 
attends a reference health area of more than 500,000 citizens and approximately 1,000 HIV+ 
patients in clinical follow-up. 
 
The clinical experience with DRV/r was retrospectively evaluated. Epidemiological, clinical 
and immunovirological features of HIV+ patients who had started ART with DRV/r were 
recorded. Previous exposition to antiretroviral drugs and drug resistance profile, when available, 
were also recorded. Genotypic resistance testing was performed according to clinical guidelines 
recommendations. Resistances to the different antiretroviral-family drugs were recorded using the 
freely available algorithm from Stanford University Drug Resistance database. The efficacy, safety 
and tolerance of the ART including DRV/r were evaluated during the study period. Efficacy was 
evaluated at 48, 96, and 144 weeks. Patients with suppressed viremia (HIV-RNA <50 copies/ml) at 
time of DRV/r initiation and patients with no data about time under DRV/r regimen were excluded 
of the efficacy analysis. In addition, patients with less than 48, 96, and 144 weeks of follow-up 
with DRV/r-based therapy were also excluded of the corresponding analysis, unless 
discontinuation of DRV/r regimen (i.e., due to toxicity). 
 
The statistical analysis was performed using the Statistical Packages for the Social Sciences 
software (SPSS 19.0, Chicago, IL). Categorical variables are presented as number of cases or 
percentage and were compared by the χ2 test or Fisheŕs exact test, when appropriate. Continuous 
variables are expressed as mean (standard deviation) and compared by non-parametric Mann–
Whitney and Kruskal–Wallis test, when appropriate. A P-value of <0.05 was considered 
statistically significant. 
RESULTS 
A total of 360 HIV-infected patients have initiated ART with DRV/r in the period 2007–2015 
but only 173 patients have signed the informed consent and therefore could be included in the 
study. Epidemiological and immunovirological characteristics of these patients were described in 
Table I. Overall, these patients had a severe immunosuppression with nadir CD4 counts values of 
154 ± 126 cell/mm3; being the CD4 nadir ≤100 cells/mm3 in 43.2% of them. Moreover, 32.1% of 
naïve patients initiated treatment with a DRV/r-based therapy at diagnosis time of an AIDS 
defining disease: Pneumocystis jiroveci pneumonia (35.7%), tuberculosis (35.7%), toxoplasmosis 
(10.7%), HIV encephalopathy (3.6%), and others (14.3%). 
  
Table I. Baseline Characteristics of HIV-Infected Patients Receiving DRV/r 
Therapy 
Variables N = 173 
Epidemiological 
Male 131 (75.7) 
Mean age (years) 32.8 ± 10.1 
Route of HIV transmission 
 
Heterosexual 51 (30.4) 
MSM 52 (31) 
IDU 60 (35.7) 
Other 5 (3) 
Nationality   
Spanish 151 (88.3) 
European 2 (1.2) 
South-American 15 (8.8) 
African 3 (1.8) 
Inmunovirological status   
Late diagnosis 67 (62) 
CD4 count at HIV diagnosis (cells/mm3) 288 ± 245 
CD4 nadir (cells/mm3) 154 ± 126 
Viral load at HIV diagnosis (log copies/ml) 5.87 ± 6.25 
CDC classification   
Category A 58 (37.7) 
Category B 26 (16.9) 
Category C 70 (45.5) 
HIV-1 genetic subtype   
Subtype B 31 (17.9) 
Subtype F 32 (18.5) 
Subtype C 3 (1.7) 
Unknown subtype 107 (61.8) 
Comorbidity 57.2% 
Viral hepatitis co-infection   
HBsAg positive 4 (2.3) 
Antibodies HCV 65 (37.6) 
HCV-RNA positive 50 (28.9) 
Neuropsyquiatric morbidity   
Drug-consumption related disorders 11 (6.4) 
Anxious-depressive syndrome 31 (17.9) 
Psychotic syndrome 7 (4) 
Other 3 (1.7) 
Chronic kidney disease (estimated glomerular 
filtration rate 30–60 ml/min) 
12 (6.9) 
  
 
Data are expressed as n (%). 
 
  
The presence of viral hepatitis co-infection, neuropsyquiatric and/or chronic kidney 
comorbidities was recognized in 57.2% of patients (Table I). Transaminase values were 
significantly higher in HIV-HCV co-infected patients (mean values of AST and ALT of 46 ± 70 
and 52 ± 93 mg/dl, respectively) compared to HIV mono-infected patients (median values of 25 ± 6 
and 26 ± 11 mg/dl, respectively; P = 0.002 [for AST] and P = 0.011 [for ALT]). In addition, 
cardiovascular risk factors were present with the following distribution: tobacco-consumption 
(37%), dyslipidaemia (25.6%), hypertension (14%), and diabetes mellitus (1.7%) while 17.5% of 
them have two or more cardiovascular risk factors. Patients with dyslipidaemia had the following 
lipid profile (mean values): 212 ± 39 mg/dl of cholesterol, 44 ± 12 mg/dl HDL-cholesterol, 
123 ± 38 mg/dl LDL cholesterol, and 232 ± 125 mg/dl triglycerides. 
 
Overall, 35.8% of patients were naïve to ART and 64.1% were treatment-experienced. Of 
them, 27.8% had been exposed to ≤3 ART regimens and 36.4% to >3 before DRV/r initiation. The 
mean time under a DRV/r-based therapy was 38 ± 27 months. Detailed information about 
immunovirological status, time since HIV infection, time under ART (including time under 
DRV/r-based therapy), previous ART regimens and reasons for discontinuation of these previous 
therapies in treatment-experience patients were exposed in Table II. 
  
Table II. Antiretroviral Therapy Characteristics and Resistance Profile in Patients Receiving DRV/r Therapy According 
Previous ART Exposure 
  Naïve (n = 62) 
Treatment-experienced ≤3 
ART lines (n  = 48) 
Treatment-experienced >3 
ART lines (n = 63) 
Time with HIV-infection until DRV/r 
initiation (months) 
17.5 ± 35.6 103.8 ± 76.2 203.7 ± 67.8 
Time with ART until DRV/r initiation 
(months) 
NA 62.7 ± 47.6 141.1 ± 44.4 
CD4 < 200 cells/mm3 at DRV/r initiation (%) 43.3 23.7 31.5 
HIV-RNA >100,000 copies/ml at DRV 
initiation (%) 
68.3 38.9 25 
Suppressed viral load (HIV-RNA <50 
copies/ml) at DRV/r initiation (%) 
0 56.1 41.9 
Time with DRV/r regimen (months) 25.9 ± 16.9 38.8 ± 26.3 49.7 ± 31.9 
Type of DRV/r regimen (%) 
   
Triple therapy 100 80.4 71 
Dual therapy 0 2.2 9.7 
Monotherapy 0 17.4 19.4 
Dosage of DRV/r (%) 
   
800 QD 100 93.3 62.7 
600 BID 0 6.7 37.3 
Previous ART regimens (%) 
   
NNRTIs-based regimen NA 60.9 83.9 
PIs-based regimen NA 60.9 98.4 
INIs-based regimen NA 6.5 6.5 
Reason for discontinuation of previous ART 
regimen (%)    
Poor adherence NA 17.4 17.7 
Virological failure NA 21.7 35.5 
Toxicity NA 41.3 11.3 
Simplification NA 6.5 27.4 
Not available data NA 13 8.1 
Resistance profile (%) 
   
Baseline NRTIs resistance 3.4 0 0 
Baseline NNRTIs resistance 3.4 7.7 0 
Baseline PIs resistance 1.7 0 0 
NRTIs resistance at virological failure NA 50 86.1 
NNRTIs resistance at virological failure NA 66.7 76.5 
PIs resistance at virological failure NA 0 58.3 
    
 
DRV/r, darunavir boosted with ritonavir; ART, antiretroviral treatment; NA, not applicable; 800 QD, 800 mg of 
darunavir + 100 mg of ritonavir, once a day; 600 BID, 600 mg of darunavir + 100 mg of ritonavir, twice a day; NNRTIs, 
non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; INIs, integrase inhibitors; NRTIs, nucleoside 
reverse transcriptase inhibitors. 
 
  
Baseline resistance test was performed in a 42.8% of patients included in the study. Regarding 
treatment-experienced patients, resistance test was performed in 63.6% of patients at virological 
failure time. Drug resistance to NRTIs, non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
and PIs drugs at baseline and at virological failure were described in Table II. 
 
The majority of patients (83.7%) initiated DRV/r in triple combination therapy, 12.2% as 
monotherapy and 4.1% as dual therapy. The mean of CD4 counts at the DRV/r initiation was 
345 ± 294 cells/mm3 and the mean viral load was 5.52 ± 5.76 log copies/ml. All naïve patients 
received dosage of 800 mg of darunavir boosted with 100 mg of ritonavir once a day (800 QD). 
Regarding treatment-experienced patients, 76.4% received 800 QD and 23.6% received 600 mg of 
darunavir boosted with 100 mg of ritonavir twice a day (600 BID). 
 
Overall, the virological suppression (HIV-RNA <50 copies/ml) was achieved in 62.9% at 48 
weeks and 73.8% at 96 and 144 weeks of DRV/r treatment (excluding patients with suppressed 
viremia at the moment of DRV/r initiation). The rate of virological suppression in naïve patients 
was 63%, 66.7%, and 63.6% at 48, 96, and 144 weeks, respectively. The rate of virological 
suppression in treatment-experienced patients was 62.7%, 78.7%, and 79.1% at 48, 96, and 144 
weeks, respectively. No significant differences in virological suppression were observed according 
to immunovirological status at DRV/r initiation neither the dosage of DRV/r, although efficacy is 
higher in treatment-experienced patients with DRV/r 600 BID (Table III). Regarding treatment-
experienced patients, efficacy at 48 weeks was 62.5% for those with triple therapy and 66.7% for 
those with dual therapy, and no significant differences were observed between both groups 
(P = 0.999). 
  
Table III. Virological Efficacy (HIV-RNA < 50 copies/mL) at 48, 96, and 144 Weeks According to the Immuno-
Virological Status and DRV/r Dosage 
 
Naïve Treatment-experienced P 
. 
48 weeks N = 54 N = 51 
 
Efficacy (%) 63 62.7 0.982 
CD4 (cells/mm3) at DRV/r initiation 
  
0.569* 
  
  
0.757** 
CD4 ≤200 56.5 57.1 
 
CD4 >200 67.7 62.5 
 
HIV-RNA (copies/ml) at DRV/r initiation 
  
0.229* 
  
  
0.526** 
HIV-RNA ≤100,000 76.5 66.7 
 
HIV-RNA >100,000 56.8 53.3 
 
Dosage of DRV/r 
  
0.352** 
800 QD 63 58.6 
 
600 BID NA 71.4 
 
96 weeks N = 33 N = 47 
 
Efficacy (%) 66.7 78.7 0.228 
CD4 (cells/mm3) at DRV/r initiation 
  
0.719* 
  
  
0.999** 
CD4 ≤200 71.4 78.9 
 
CD4 >200 63.2 81.8 
 
HIV-RNA (copies/ml) at DRV/r initiation 
  
0.456*,** 
HIV-RNA ≤100,000 76.9 81.8 
 
HIV-RNA >100,000 60 71.4 
 
Dosage of DRV/r 
  
0.150** 
800 QD 66.7 69.2 
 
600 BID NA 90 
 
144 weeks N = 22 N = 43 
 
Efficacy (%) 63.6 79.1 0.180 
CD4 (cells/mm3) at DRV/r initiation 
  
0.999* 
  
  
0.701** 
CD4 ≤200 63.6 82.4 
 
CD4 >200 63.6 75 
 
HIV-RNA (copies/ml) at DRV/r initiation 
  
0.999*,** 
HIV-RNA ≤100,000 60 77.4 
 
HIV-RNA >100,000 66.7 83.3 
 
Dosage of DRV/r 
  
0.149** 
800 QD 63.6 66.9 
 
600 BID NA 89.5 
 
    
 
*For naïve patients. 
**For treatment-experienced patients 
 
  
All naïve patients with baseline resistance achieved virological suppression at 48 weeks. 
Treatment-experienced patients with previous resistance to NRTIs achieved virological 
suppression in 76%, 78.3%, and 76.2% at 48, 96, and 144 weeks, respectively. Those with 
previous resistance to NNRTIs achieved virological suppression in 58.3%, 71.4%, and 68.4% at 
48, 96, and 144 weeks, respectively. Interestingly, treatment-experienced patients with previous 
resistance to PIs achieved virological suppression in 83.3% at 48 and 96 weeks and 82.4% at 144 
weeks. 
 
Of note, 47.1% of treatment-experienced patients had undetectable viremia at the time of 
DRV/r initiation. All patients with triple and dual therapy and suppressed viremia at DRV/r 
initiation maintained virological suppression during follow-up. In two patients receiving DRV/r as 
monotherapy, the addition of two NRTI was required due to virological failure but in both cases 
they achieved virological suppression afterwards. 
 
During the follow-up, 9.3% of patients who had initiated triple-therapy with DRV/r switch to 
DRV/r monotherapy while 8.5% switch to dual therapy with DRV/r. In all these cases, patients 
maintained virological suppression after simplification. 
 
Overall, 82.6% of patients maintained DRV/r therapy during the study period. The main causes 
for DRV/r discontinuation were adverse events (10.5%), switch to simplification strategies (3.5%), 
virological failure (1.7%; all of them with HIV-RNA values <200 copies/ml) and drug-drug 
interactions (1.7%). Pharmacological interactions were present with telaprevir, pulmonary 
hypertension treatment and anti-deppressive medication. 
 
Regard the safety and tolerability under DRV/r, the most part of patients (89.5%) had no 
relevant adverse events. The main recognized adverse events were gastrointestinal (3.6%) and 
cutaneous (2.4%) while 4.5% had other adverse events including dyslipidaemia or dizziness, 
which are described in detail in Table IV. Only two patients of all who discontinued therapy with 
DRV/r due to toxicity were taking 600 BID. 
  
Table IV. Toxicity in Patients Who Discontinued DRV/r-Based Therapy 
ART regimen N (%) Toxicity 
Overall 173 (100) 10.5% 
Triple-therapy 145 (83.8) 12% 
TDF/FTC + DRV/r 92 (53.2) 
Cutaneous (n = 3) 
Gastrointestinal (n = 2) 
Othera (n = 6) 
ABC/3TC + DRV/r 29 (16.8) 
Gastrointestinal (n = 2) 
Otherb (n = 2) 
RAL + ETR + DRV/r 8 (4.6) 
 
RAL + MVC + DRV/r 4 (2.3) 
 
TDF/FTC + RAL + DRV/r 6 (3.5) Cutaneous (n = 1) 
TDF/FTC + MVC + DRV/r 2 (1.2) Gastrointestinal (n = 1) 
Other 4 (2.2) 
 
Dual therapy 7 (4.1) 0% 
MVC + DRV/r 2 (1.2) 
 
3TC + DRV/r 1 (0.6) 
 
RAL + DRV/r 3 (1.7) 
 
ETR + DRV/r 1 (0.6) 
 
Monotherapy 21 (12.1) 4.8% 
  
 
Gastrointestinal (n = 1) 
   
 
TDF/FTC, tenofovir and emtricitabine coformulated; ABC/3TC, abacavir and lamivudine 
coformulated; RAL, raltegravir; ETR, etravirine; MVC, maraviroc; 3TC, lamivudine. 
a Other includes: dyslipidemia, trombopenia, renal toxicity (two patients), dizziness and sexual 
disfunction. 
b Other: not specified type of toxicity. 
DISCUSSION 
DRV/r represents the second generation of PIs with demonstrated antiviral activity against 
HIV+ treatment-naïve and experienced patients harbouring protease resistance mutations to the 
first PIs generation [Clotet et al., 2007; Madruga et al., 2007; Ortiz et al., 2008]. The efficacy and 
safety of DRV/r have been extensively demonstrated in different clinical trials and current HIV 
treatment guidelines considered DRV/r in combination with tenofovir/emtricitabine as a 
recommended regimen for treatment-naïve patients [DHHS, 2015; EACS, 2015]. However, there 
are few studies evaluating the long-term efficacy and safety of DRV/r in the real-life setting, and 
all of them only include treatment-experienced patients [Young et al., ; Benea et al., 2014; 
Biscione et al., 2014; Ribeiro et al., 2014]. 
 
Herein, we retrospectively evaluated the clinical experience with DRV/r since its approval in 
2007 until September 2015 in 173 HIV+ patients in clinical follow-up in Northwest Spain. This 
patient population is characterized for high HIV-RNA levels at the moment of DRV/r initiation 
(mean of 5.52 log copies/ml) and severe immunosuppression in most cases (62% had a late 
diagnosis and 43% had CD4 nadir <100 cells/mm3). Moreover, 64.1% were treatment-experienced 
and of them 36.5% had been exposed to >3 ART regimens. However, and despite this 
unfavourable clinical status, the overall rate of virological suppression was 62.9% at 48 weeks and 
73.8% at 96 and 144 weeks of DRV/r-based therapy. No differences in efficacy were observed 
between naïve and treatment-experienced patients at 48 weeks (63% vs. 62.7%, P = 0.982), at 96 
weeks (66.7% vs. 78.7%, P = 0.228) and 144 weeks (63.6% vs. 79.1%, P = 0.180). These data 
highlight the high potency of DRV/r irrespectively of the HIV-RNA levels and the immune status 
but also its ability to be used in rescue therapies for patients who have failed several ART 
regimens. Of note, only 1.7% of patients discontinue DRV/r treatment due to virological failure 
and all of them with HIV-RNA values <200 copies/ml. 
 
In most cases DRV/r was used as part of triple therapy strategies (83.7%) but also in 
monotherapy (12.2%) and dual therapy (4.1%). DRV/r may be particularly suited for both 
monotherapy or dual therapy due to its high genetic barrier and its favourable safety and 
pharmacokinetic profile that allow to be administered once daily [Rabi et al., 2013]; and the recent 
introduction of the coformulation of darunavir with cobicistat in only one pill may optimize 
dosage and adherence. Both strategies might be particularly attractive in cases of NRTIs-related 
intolerance or toxicity and its use in these setting is recognized in some guidelines [EACS, 2015; 
Panel de expertos de GeSIDA, 2015]. Dual and monotherapy were used only in treatment-
experienced patients in our study. The rate of virological suppression in patients with dual therapy 
was 66.7% at 48 weeks, and no differences in efficacy were observed compared to treatment-
experienced patients with triple therapy. In addition, all patients under dual therapy and virological 
suppression at DRV/r initiation, maintained efficacy during the follow-up. In the case of DRV/r 
monotherapy, randomized clinical trials and experience in the real life have shown optimized 
results in simplification strategies in selected HIV+ patients (absence of chronic hepatitis B 
infection, HIV plasmatic viral load <50 copies/ml during at least 6 months and absence of 
resistance mutations in protease gene or previous virological failure to PIs [Katlama et al., 2010; 
Santos et al., 2012; Arribas et al., 2016]. In this study, all but two patients receiving DRV/r 
monotherapy maintain virological suppression (probably due to inadequate adherence). 
 
DRV/r was well tolerated in clinical trials, with a better profile than other PIs regarding to 
diarrhoea, gastrointestinal tolerability and lipid concentrations. Treatment discontinuation due to 
adverse events in clinical trials varies between 4% and 7% [Clotet et al., 2007; Madruga et al., 
2007]. In this study, 10.5% of patients have discontinued DRV/r treatment due to adverse events 
being gastrointestinal toxicity (3.6%) and cutaneous reaction (2.4%) the most frequent. Although 
this percentage is slightly higher than in other studies, this might be due to the specific inclusion 
criteria required for clinical trials that do not reflect the real-life scenario. Of note, those patients 
under DRV/r monotherapy or dual therapy had little adverse events. Although the number of 
patients under NRTIs-sparing regimen is limited, some of these adverse reactions might be 
potentially attribute to the use of NRTI. 
 
There are some limitations in this study. This is a retrospective and observational study, 
therefore, these results could not be compared with other obtained in clinical trials or study cohorts 
due to the heterogeneity of the study populations, studies design, inclusion criteria or endpoints. In 
addition, only those patients who have signed informed consent were included in the study, but 
they do not represent all the patients treated with a DRV/r-based regimen, therefore, possible bias 
could exist. Moreover, data of drug resistance mutations were not available in more than a half of 
patients (at baseline) and almost 40% (at virological failure). However, considering the rates of 
virological suppression in treatment-experienced patients, over 80% in patients with previous PIs 
resistances, it seems that if drug resistance mutations were present, they had little impact on the 
virological response to DRV/r. Regarding evaluation of safety, grade of toxicity of DRV/r was not 
recorded in most of patients, and it is possible that mild adverse events were present in some of 
them. Nonetheless, this mild toxicity would not have relevant clinical consequences as most of the 
patients maintained DRV/r-based therapy. 
 
In conclusion, this study demonstrated the prolonged efficacy and safety profile of DRV/r for 
the treatment of HIV-infected patients even in patients with an unfavourable viro-immunological 
status in the real-life setting. Moreover, DRV/r might be considered a good therapeutic option for 
those patients who had failed to several ART regimens or for those with intolerance to other ART 
drugs as mono- or dual-based therapies.  
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